Pharma giant Merck agreed to buy rare blood and bone cancer biotech Terns Pharmaceuticals in a deal valued at $6.7 billion, the companies announced Wednesday.
Why it matters: It's Merck's third big recent acquisition as it prepares for blockbuster cancer drug Keytruda to come off patent.
